Atomoxetine is a prescription medication used primarily to treat attention-deficit/hyperactivity disorder (ADHD) in adults and children. It is available as a generic pill in strengths of 10 mg, 18 mg, and 25 mg and is marketed under brand names such as Strattera. In Hong Kong, atomoxetine is classified as a prescription-only (Rx) drug and is regulated by the Department of Health.
Atomoxetine belongs to the class of selective norepinephrine reuptake inhibitors (SNRIs). By blocking the norepinephrine transporter (NET) on nerve terminals, it increases the concentration of norepinephrine in the synaptic cleft. Elevated norepinephrine enhances signaling in brain regions involved in attention, impulse control, and executive function, which helps reduce core ADHD symptoms such as inattention, hyperactivity, and impulsivity.
In Hong Kong, atomoxetine is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older. The medication is indicated for both the hyperactive-impulsive and inattentive presentations, as well as the combined type. It may be prescribed as a single therapy or as part of a comprehensive ADHD management plan that includes behavioral interventions.
Atomoxetine has been investigated for several off-label indications. Evidence from randomized controlled trials and meta-analyses suggests potential benefit in:
Disclaimer: Off-label use of atomoxetine requires careful medical supervision and an individualized risk-benefit assessment. These applications are not approved by the Hong Kong Department of Health.
These effects are usually mild to moderate and often improve after the first few weeks of therapy.
General advice: Patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and vitamins to their healthcare provider before starting atomoxetine.
Standard dosing: Therapy typically begins with a 10 mg pill taken once daily in the morning. The dose may be increased by the prescriber, usually in increments of 10 mg, to a maximum of 25 mg per day based on clinical response and tolerability.
Special populations:
Children (≤ 70 kg): Starting dose often 0.5 mg/kg, adjusted upward in 10 mg steps.
Patients with CYP2D6 poor metabolizer status: Lower initial dose (e.g., 10 mg) and slower titration are recommended.
Elderly or those with hepatic impairment: May require a reduced dose; clinicians should monitor liver enzymes.
Administration: Swallow the pill whole with a full glass of water. Do not crush or split the tablet unless instructed, as this may affect drug release.
Missed dose: Take the missed dose as soon as remembered on the same day; do not double the next dose.
Overdose: Symptoms may include vomiting, agitation, tachycardia, and hypertension. Seek emergency medical care; supportive measures are the mainstay of treatment.
Discontinuation: Atomoxetine can be stopped abruptly, but tapering may be advisable for patients who have been on high doses for extended periods to minimize rebound ADHD symptoms.
Regular follow-up appointments (typically every 4-6 weeks during titration) allow the prescriber to assess efficacy, tolerability, and the need for dose modifications.
This article provides educational information about atomoxetine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Atomoxetine is a non-stimulant that selectively inhibits norepinephrine reuptake, whereas stimulants (e.g., methylphenidate, amphetamines) increase dopamine and norepinephrine release. This difference results in a lower potential for abuse and generally a smoother daily symptom control without the “peak-trough” effect seen with stimulants.
Atomoxetine can raise blood pressure and heart rate. Patients with uncontrolled hypertension should avoid the drug, while those with well-managed blood pressure may use it under close monitoring of cardiovascular parameters.
Limited data exist on atomoxetine excretion in breast milk. Because of potential exposure to the infant, the medication is usually discouraged during lactation unless the therapeutic benefit to the mother clearly outweighs the possible risk to the child.
Most individuals notice a reduction in inattentive symptoms within 1-2 weeks, but full therapeutic effect may require 4-6 weeks of consistent dosing.
Some sleep aids contain antihistamines or melatonin, which generally have minimal interaction with atomoxetine. However, sedating antihistamines may counteract the insomnia-reducing effect of atomoxetine, so patients should discuss any OTC sleep products with their prescriber.
Yes, but bring the original prescription label, a copy of the prescribing doctor’s note, and keep the medication in its original container. Some countries require a declaration for psychotropic or controlled-risk medications, so verify requirements before travel.
If you realize the missed dose on the same day, take it as soon as possible. If it is close to bedtime, skip the dose and resume the regular schedule the next morning. Do not double up to make up for the missed dose.
There are no strict dietary restrictions. A high-fat meal may slow absorption slightly, but this does not usually affect overall effectiveness. Maintaining a balanced diet helps mitigate appetite-related side effects.
Decreased appetite can lead to modest weight loss, especially during the initial weeks of treatment. Most adults experience stabilization after the first month; ongoing weight monitoring is advisable.
Generic atomoxetine contains the same active ingredient, strength, dosage form, and bioavailability as the branded product (e.g., Strattera). Regulatory approval ensures therapeutic equivalence, making it an effective and more affordable option.
